Arbutus Biopharma

8900 Glenlyon Parkway
Suite #100
British Columbia,
V5J 5J8

Tel: 604-419-3200
Fax: 604-419-3201


Show jobs for this employer

About Arbutus Biopharma

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.


October 6, 2005


CEO: Mark Murray

CMO (Medical): Mark Kowalski

CFO: Bruce Cousins

CSO (Scientific): Michael Sofia

CTO: Peter Lutwyche


Please click here for clinical trial information.

403 articles with Arbutus Biopharma